Clinical Trials ·
Retatrutide (LY3437943) demonstrates potential for weight management in adults with obesity or overweight. This Phase 2 clinical trial investigates the effects of once-weekly subcutaneous administration of retatrutide at various doses compared to placebo, focusing on participants with weight-related comorbidities.
What this source covers
This source details a Phase 2, multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of retatrutide in adults who are either overweight or have obesity, specifically those without type 2 diabetes. Participants were randomized to receive retatrutide at maintenance doses of 1, 4, 8, or 12 mg, or a placebo, administered weekly for a total of 48 weeks, followed by a 4-week safety follow-up. The primary outcome measure is the percentage change in body weight at Week 24, with additional assessments of weight, anthropometric measurements, and safety through Week 48.
Why it matters for Retatrutide research
This study is significant as it contributes to the understanding of retatrutide's potential role in managing obesity, a condition that poses numerous health risks. By evaluating multiple dosing regimens, the trial aims to identify effective strategies for weight management in individuals with obesity or overweight, particularly those with associated comorbidities. The findings could inform future clinical practices and guidelines regarding the use of retatrutide as a therapeutic option.
Key findings or claims
- The study is a Phase 2 trial evaluating retatrutide versus placebo in adults with obesity or overweight.
- Participants received once-weekly subcutaneous doses of retatrutide or placebo for 48 weeks.
- The primary efficacy evaluation focuses on the percent change in body weight at Week 24.
- Two maintenance dose levels (4 mg and 8 mg) include alternative escalation schedules to assess tolerability.
- Safety assessments will continue through Week 48 following the treatment phase.
Context and prior work
Retatrutide is part of a broader class of medications that target the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways, which are known to play a role in appetite regulation and glucose metabolism. Previous research has highlighted the efficacy of GLP-1 receptor agonists in promoting weight loss and improving metabolic health, positioning retatrutide within this context as a promising candidate for obesity management. The ongoing exploration of retatrutide's mechanisms and outcomes will contribute to the evolving landscape of obesity treatment options.
Practical takeaways for researchers
Researchers should note the importance of dose escalation in evaluating the tolerability and efficacy of retatrutide. The structured approach to assessing both weight change and safety outcomes provides a comprehensive framework for understanding the drug's potential impact on obesity management. Future studies may benefit from exploring long-term effects and comparisons with other therapeutic agents in this class.
FAQ
What is retatrutide?
Retatrutide is a medication being investigated for its efficacy in weight management among adults with obesity or overweight.
How is retatrutide administered?
Retatrutide is administered subcutaneously once a week.
What are the primary outcomes of the study?
The primary outcome is the percentage change in body weight at Week 24 of the treatment.
Source: ClinicalTrials.gov · NCT07467447 · published 2026-03-12.